Molecular changes in the development of prostate cancer
DOI:
https://doi.org/10.33448/rsd-v10i16.23969Keywords:
Prostate cancer; Molecular alterations; Genes ETS.Abstract
Introduction: Prostate cancer (PC) is the second most diagnosed in the male population in the world. Clinically, PC is subdivided into primary cancer, castration-resistant metastatic prostate cancer, and neuroendocrine prostate cancer. Objective: to describe the main molecular changes necessary for the development of primary prostate cancer (PCa). Methodology: this is a descriptive literature review. The databases PUBMED, SCIELO, Science Direct and Academic Google and National Cancer Institute (INCA) were used. The inclusion/exclusion criteria were articles from 2015 to 2021, available in Portuguese, English and Spanish. Results and discussion: the molecular bases of PC present several genomic alterations such as mutations, alterations in the number of copies of DNA, rearrangements and gene fusions. For primary cancer, the most prevalent genetic alterations are alterations in the ETS family genes such as ERG gene fusions (which occur in 50% of cases and mutations mainly in the CHD1, SPOP and BRCA1 or BRCA2 genes). In castration-resistant metastatic prostate cancer, the most prevalent genetic alteration alters androgen receptors and oncosuppressors (e.g. PTEN and TP53). Conclusion: alterations in genetic and epigenetic levels in specific genes regulated by androgen hormones are closely related to the pathogenesis of PC. These data are of paramount importance for understanding the pathophysiological mechanism of this condition, as well as providing the basis for a more specific treatment.
References
Arias,E., Astudillo, P., Manterola.C. (2015). Segunda neoplasia após tratamento para câncer de próstata localizado Segunda neoplasia após tratamento de câncerde próstata localizado. Actas Urológicas Españolas, 36(10), 583-589. DOI: https://doi.org/10.1016/j.acuro.2011.10.012.
Biblioteca Virtual em Saúde do Ministério da Saúde (BVSMS). (2015). Câncer de próstata. Acesso em: https://bvsms.saude.gov.br/bvs/dicas/137cancer_prostata.html.
Boysen, G. et al. (2019). SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clin Cancer Res, 24(22) 5585–5593. DOI: 10.1158/1078-0432.CCR-18-0937.
Brandão, A., Paulo, P., Teixeira, M. R. (2020). Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int J Mol Sci, 21(14), 1-24. DOI: 10.3390/ijms21145036.
Brasileiro-filho, G. (2019). Bogliolo Patologia Geral. 9ª edição. Rio de Janeiro: Guanabara Koogan.
Chinaranagari, A., Sharma, P., Bowen, N. J., Chaudhary, J. (2018). Prostate Cancer Epigenome. Methods Mol Biol, 125–140. DOI: 10.1007/978-1-4939-1804-1_7.
Coutinho, M. P. L., Costa, J. A., Oliveira, A. R. (2018). A relação entre masculinidade e câncer de próstata: uma revisão sistemática. Revista Principia. (43), 11-22.
Feng, F. Y., Brenner, C. J., Hussain, M., Chinnaiyan, A. M. (2015). Molecular Pathways: Targeting ETS Gene Fusions in Cancer. Clin Cancer Res, 20(17), 4442–4448. DOI: 10.1158/1078-0432.CCR-13-0275.
Gerhauser, C. et al. (2020). Molecular evolution of early onset prostate cancer identifies molecular risk markers and clinical trajectories. Cancer Cell, 34(6), 996–1011. DOI: 10.1016/j.ccell.2018.10.016.
Gyorgy Petrovics, G. et al. (2019). Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis, 22(3), 406–410. DOI: 10.1038/s41391-018-0114-1.
He, Z., Duan, X., Zeng, G. (2019). Identification of potential biomarkers and pivotal biological pathways for prostate cancer using bioinformatics analysis methods. PeerJ, 1-21. DOI: 10.7717/peerj.7872.
INSTITUTO NACIONAL DE CÂNCER - INCA. Como surge o câncer? Disponível em: < https://www.inca.gov.br/como-surge-o-cancer> Acesso em: 04 jan. 2021.
INSTITUTO NACIONAL DE CÂNCER - INCA. Estimativa 2020. Disponível em: <https://www.inca.gov.br/estimativa/introducao> Acesso em: 03 jan. 2021.
INSTITUTO NACIONAL DE CÂNCER - INCA. Introdução. Disponível em: <https://www.inca.gov.br/estimativa/introducao> Acesso em: 06 maio. 2021.
INSTITUTO NACIONAL DE CÂNCER - INCA. O que é câncer? Disponível em: <https://www.inca.gov.br/o-que-e-cancer> Acesso em: 03 jan. 2021.
INSTITUTO NACIONAL DE CÂNCER - INCA. Síntese de Resultados e Comentários. Disponível em: < https://www.inca.gov.br/estimativa/sintese-de-resultados-e-comentarios#:~:text=A%20estimativa%20mundial%20aponta%20o,33%2C1%2F100%20mil. > Acesso em: 06 maio. 2021.
Junejo, N. N., AlKhateeb, S. S. (2020). BRCA2 gene mutation and prostate cancer risk. Saudi Med J, 41(1), 9–17. DOI: 10.15537/smj.2020.1.24759.
Kgatle, M. M., Kalla,A. A., Islam, M. M., Sathekge, M., Moorad, R. (2016). Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy. Prostate Cancer. 1-11. DOI: 10.1155/2016/5653862.
Marshall, C. H., Fu, W., Wang, H., Baras,A. S., Lotan, TM L., Antonarakis, E. S. (2019). Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: Association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis, 22(1), 59–65. DOI: 10.1038/s41391-018-0086-1.
Morbeck,I. A. P., Gadia,R., Chaves, N. R., Santos,M. (2019). Câncer de próstata. Diretrizes Oncológicas. 1-24. Acesso em: https://diretrizesoncologicas.com.br/wp-content/uploads/2019/10/Diretrizes-oncologicas_separata_Prostata.pdf.
Morbeck,I. A. P., Gadia,R., Chaves, N. R., Degrande, F. A. M., Leite, E. T. T. (2019). Câncer de próstata. Diretrizes Oncológicas. 385-404. Acesso em: https://diretrizesoncologicas.com.br/wpcontent/uploads/2019/01/Diretrizes-oncolo%CC%81gicas-2_Parte27.pdf.
Mota, T. R., Barros, D. P. O. (2019). Profile of prostate cancer patients in the reference hospital in the Pernambuco state. Rev. bras. anal. Clin. Recife, v.50, n.4, p. 334-338. DOI: 10.21877/2448-3877.201900766.
Pinheiro,E. S., Carneiro,P. H. G., Araújo,E. H.V., Oliveira,A. S.O., Valadão,D. V.; Prado, S. C., Crispim,L.F. (2021). Diagnósticos de hiperplasia benigna e câncer de próstata em um município do sudoeste goiano: análise de 20 anos. Brazilian Journal of Development, 7(1), 3963-3974. Doi: 10.34117/bjdv7n1-268.
Rodrigues, L. U. et al. (2016). Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate câncer. Cancer Res, 75(6), 1021–1034. DOI: 10.1158/0008-5472.CAN-14-1596.
Sandoval, G. J. et al. (2018). Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis. Mol Cell, 71(4), 554–566. DOI: 10.1016/j.molcel.2018.06.040.
Sarris, A. B., candido, F. J. L. F., Filho, C. R. P.; Staichak, R. L.; Torrani. A. C. K., Sobreiro, B. P. (2018). Câncer de próstata: uma breve revisão atualizada. Repositório digital institucional UFPR, Curitiba, v.19, n.1, p. 137-151.
Seemann, T., Pozzobom, F., Vieira, M. C. S., Boing, F., Machado, Z., Guimarães, A. C. A. (2018). Influence of symptoms of depression on the quality of life of mendiagnosed with prostate cancer. Rev. bras. geriatr. gerontol. Rio de Janeiro, v.21, n.1, p. 70-78.
Sun, J., Li, S., Wang, F., Fan, C., Wangautor, J. (2019). Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis. BMC Med Genet, (20), 1-9. DOI: 10.1186/s12881-019-0923-7.
Taylor, R. A. et al. (2017). Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun. DOI: 10.1038/ncomms13671.
The Cancer Genome Atlas Research Network. (2015). The Molecular Taxonomy of Primary Prostate Cancer. Cell, 163(4), 1011-1025. DOI: https://doi.org/10.1016/j.cell.2015.10.025.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Açucena de Oliveira Borges; Juliana Paniago Souza; Letícia Góes Pereira; Eriston Vieira Gomes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
